
Faculty, Staff and Student Publications
Publication Date
2-27-2023
Journal
Nature Communications
Abstract
Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. This analysis evaluates acquired resistance mechanisms to second-line osimertinib (n = 78) in patients with EGFR T790M advanced non-small cell lung cancer (NSCLC) from AURA3 (NCT02151981), a randomized phase 3 study comparing osimertinib with chemotherapy. Plasma samples collected at baseline and disease progression/treatment discontinuation are analyzed using next-generation sequencing. Half (50%) of patients have undetectable plasma EGFR T790M at disease progression and/or treatment discontinuation. Fifteen patients (19%) have >1 resistance-related genomic alteration; MET amplification (14/78, 18%) and EGFR C797X mutation (14/78, 18%).
Keywords
Humans, Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms, Mutation, Protein Kinase Inhibitors, Disease Progression, Cancer, Lung cancer, Targeted therapies
DOI
10.1038/s41467-023-35962-x
PMID
36849516
PMCID
PMC9971022
PubMedCentral® Posted Date
2-27-2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes